tetano
Editor, Senior Moderator
CEN Case Rep
. 2022 Jan 9.
doi: 10.1007/s13730-021-00671-1. Online ahead of print.
Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan
Kanako Terakawa[SUP] 1 [/SUP], Daisuke Katagiri[SUP] 2 [/SUP], Keiki Shimada[SUP] 1 [/SUP], Lubna Sato[SUP] 3 [/SUP], Hideki Takano[SUP] 1 [/SUP]
Affiliations
Abstract
Controlling excessive cytokine secretion is a crucial therapeutic strategy for managing coronavirus disease 2019 (COVID-19). Patients on dialysis are at a high risk of severe disease, given abnormal immune responses that can lead to prolonged inflammation. Moreover, patients undergoing dialysis have limited treatment options, as neither remdesivir nor baricitinib is available. The novel neutralizing monoclonal antibody cocktail REGEN-COV (formerly known as REGN-COV2; casirivimab/imdevimab), recently approved in Japan, is a promising drug for preventing severe diseases. However, there are few reports regarding its use in patients undergoing dialysis in Japan. Herein, we report the safe use of antibody cocktail therapy in patients with COVID-19 on hemodialysis receiving maintenance dialysis in Japan. Infusion reactions were not observed during administration. Due to the increasing number of patients with COVID-19 and the limited capacity of the healthcare system, antibody cocktail therapy needs to be enhanced. Antibody cocktail therapy for severe diseases can be safely administered to patients undergoing dialysis who do not require supplemental oxygen.
Keywords: COVID-19; Casirivimab/imdevimab; Hemodialysis.
. 2022 Jan 9.
doi: 10.1007/s13730-021-00671-1. Online ahead of print.
Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan
Kanako Terakawa[SUP] 1 [/SUP], Daisuke Katagiri[SUP] 2 [/SUP], Keiki Shimada[SUP] 1 [/SUP], Lubna Sato[SUP] 3 [/SUP], Hideki Takano[SUP] 1 [/SUP]
Affiliations
- PMID: 35000134
- DOI: 10.1007/s13730-021-00671-1
Abstract
Controlling excessive cytokine secretion is a crucial therapeutic strategy for managing coronavirus disease 2019 (COVID-19). Patients on dialysis are at a high risk of severe disease, given abnormal immune responses that can lead to prolonged inflammation. Moreover, patients undergoing dialysis have limited treatment options, as neither remdesivir nor baricitinib is available. The novel neutralizing monoclonal antibody cocktail REGEN-COV (formerly known as REGN-COV2; casirivimab/imdevimab), recently approved in Japan, is a promising drug for preventing severe diseases. However, there are few reports regarding its use in patients undergoing dialysis in Japan. Herein, we report the safe use of antibody cocktail therapy in patients with COVID-19 on hemodialysis receiving maintenance dialysis in Japan. Infusion reactions were not observed during administration. Due to the increasing number of patients with COVID-19 and the limited capacity of the healthcare system, antibody cocktail therapy needs to be enhanced. Antibody cocktail therapy for severe diseases can be safely administered to patients undergoing dialysis who do not require supplemental oxygen.
Keywords: COVID-19; Casirivimab/imdevimab; Hemodialysis.